Oncogenuity, Inc.

Pipeline

Taking Gene Silencing to the DNA Level

At Oncogenuity, our extensive research shows that ONCOlogues have promising potential for treating a broad range of clinical conditions with substantial unmet need thanks to their ability to target a wide variety of mutations with potentially limited side effects.

We have established proof-of-concept in a pre-clinical setting for various cancers. Our lead product candidate targets the KRAS G12D mutation, which plays a key role in many cancer types and was previously considered undruggable. We are also engaged in discovery work to validate ONCOlogues’ potential in treating genetic disorders and viruses, including COVID-19.

ONCOlogues Preclinical Phase 1 Phase 2

KRAS G12D
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started

Covid-19/Coronaviruses
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started

Various Genetic Disorders Targeted by Gene Silencing
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started

Viruses With Unmet Need
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started

KRAS

Our most advanced program targets the KRAS mutation G12D, a protein that drives cell growth in many hard-to-treat cancers, including pancreatic and colorectal cancers.

Indications

  • G12D
  • G12C
  • G12V

Many devastating cancers result from KRAS G12D mutations and lack any targeted therapies, including:

  • ~35% of pancreatic cancers
  • ~12% of colorectal cancers
  • ~5% of endometrial cancers and NSCLC

1Estimates based on American Cancer Society incidence estimates and frequency of mutation reported in TCGA PanCancer Atlas Studies

~183K

Annual KRAS G12D Patient Population (US/EU)1

1Estimates based on American Cancer Society incidence estimates and frequency of mutation reported in TCGA PanCancer Atlas Studies

~$10B+

Potential US/EU Market for KRAS G12D

2Estimated pricing based on MEK/BRAF combination therapy

COVID-19/ Coronaviruses

Our ONCOlogue platform also has the potential to attack viral RNA by interrupting viral transcription and replication before the virus can proliferate. We are currently investigating new sequences aimed at COVID-19, seeking to validate ONCOlogues as a treatment for current and future coronavirus outbreaks.

Various Genetic Disorders

We are actively developing new ONCOlogues to explore the range of conditions our technology can target, including mutations leading to certain genetic disorders. Thanks to ONCOlogues’ high specificity and low off-target toxicity, they can potentially be administered at effective doses with few side effects, ultimately providing patients with safer and more effective treatment options.

Potential Indications

  • Familial Amyloid Neuropathies
  • Hemophilia A
  • Homozygous Familial Hypercholesterolemia

Viruses with Unmet Needs

Currently, we are evaluating ONCOlogues’ vast potential application toward viruses and other diseases. Single-stranded RNA genomes like those found in coronaviruses and other viral targets are more easily accessible than cellular DNA and are strong candidates for the ONCOlogue platform.

Potential Indications

  • Hepatitis B
  • Dengue Fever
  • Respiratory Syncytial Virus